WP
KZR

Woodline Partners’s Kezar Life Sciences KZR Stock Holding History

Woodline Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,555
Closed -$125K – 996
2025
Q1 		$125K Buy
+25,555
New +$155K ﹤0.01% 885
2022
Q4 		– Sell
-58,018
Closed -$5M – 810
2022
Q3 		$5M Buy
+58,018
New +$5.64M 0.07% 288

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Woodline Partners's KZR Position: Q2 2025 in Review

Woodline Partners sold out of Kezar Life Sciences (KZR) in Q2 2025, closing a stake of 25,555 shares — an estimated $125K sold.

Woodline Partners first reported a position in KZR in Q3 2022 and held it in 2 quarters. The position peaked at $5M in Q3 2022. 40 funds tracked by Wall St. Rank hold KZR as of Q2 2025.

  • Woodline Partners reported no remaining Kezar Life Sciences position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 25,555 Kezar Life Sciences shares in Q2 2025, an estimated $125K.
  • Woodline Partners first reported a position in Kezar Life Sciences in Q3 2022 and held it in 2 quarters.
  • Woodline Partners's Kezar Life Sciences position peaked at $5M in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.